Quality of harvest and role of cell dose in unrelated bone marrow transplantation: An Italian Bone Marrow Donor Registry–Gruppo Italiano Trapianto di Midollo Osseo Study
- 25 November 2013
- journal article
- Published by Taylor & Francis in Hematology
- Vol. 19 (1) , 1-9
Abstract
In this study, we investigated the factors affecting cell dose harvest and the role of cell dose on outcome. We analysed data from a cohort of 703 patients who underwent unrelated bone marrow transplantation facilitated by IBMDR in GITMO centers between 2002 and 2008. The median-infused cell doses is 3.7 × 10(8)/kg, the correlation between the nucleated cells requested from transplant centers and those harvested by collection centers was adequate. A harvested/requested cells ratio lower than 0.5 was observed only in 3% of harvests. A volume of harvested marrow higher than the median value of 1270 ml was related to a significant lower infused cell dose (χ(2): 44.4; P < 0.001). No patient- or donor-related variables significantly influenced the cell dose except for the recipient younger age (χ(2): 95.7; P < 0.001) and non-malignant diseases (χ(2): 33.8; P < 0.001). The cell dose resulted an independent predictor factor for a better outcome in patients affected by non-malignant disease (P = 0.05) while early disease malignant patients receiving a lower cell dose showed a higher risk of relapse (P = 0.05).Keywords
This publication has 29 references indexed in Scilit:
- Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation GroupBone Marrow Transplantation, 2010
- Monitoring the international use of unrelated donors for transplantation: the WMDA annual reportsBone Marrow Transplantation, 2010
- Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2007
- Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrowBlood, 2003
- Decreased treatment failure in recipients of HLA‐identical bone marrow or peripheral blood stem cell transplants with high CD34 cell dosesBritish Journal of Haematology, 2003
- Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantationBlood, 2002
- Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European SurveyJournal of Clinical Oncology, 2002
- DEATH BY GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH HLA MISMATCH, HIGH RECIPIENT AGE, LOW MARROW CELL DOSE, AND SPLENECTOMYTransplantation, 1985
- Bone Marrow Transplantation for Acute Myelogenous LeukemiaJAMA, 1983
- Marrow Transplantation for Treatment of Aplastic AnemiaNew England Journal of Medicine, 1977